Lilly says obesity pill can replace shot after weight loss [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
their weight loss after switching from injectable forms of its Zepbound GLP-1 drug and Novo Nordisk's Wegovy. In Lilly's Phase 3 trial, patients who switched to the daily pill from Wegovy after one year maintained their weight loss with an average gain of 0.9 kilograms, while those who switched from Zepbound saw an average gain of 5 kilograms. Lilly's stock was up 2.3% on Thursday as of 12:45 p.m. ET. The pharma giant has already filed for FDA approval of the pill as an initial treatment for obesity, and in November the FDA awarded the pill a priority review voucher, which could expedite its review timeline to a few months. This new trial indicates it could also be used as a maintenance therapy for patients who no longer want to take the injectable form of the drug. Many patients regain weight once they stop a GLP-1 drug, now only available as an injection. “If approved for the treatment of obesity, orforglipron could provide a convenient alternative for the millions of indi
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Prediction: 1 Healthcare Giant Set to Soar in 2026 [Yahoo! Finance]Yahoo! Finance
- Obesity pill race heats up [CNBC]CNBC
- Eli Lilly Obesity Pill Maintains Weight Loss After Wegovy, Zepbound [Yahoo! Finance]Yahoo! Finance
- Rise of Direct-to-Patient GLP-1 Sales Shakes Up Care Models, HCPs Split on Pharma's Expanding Role [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk (NVO) Fell Following a Profit Warning Release [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website